Rein Therapeutics, Inc. (RNTX) company profile
Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%
About Rein Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical business that develops novel therapeutics targeting orphan pulmonary and fibrosis indications with limited or no approved therapies. Its primary pipeline candidate is LTI-03, an inhaled peptide therapeutic derived from the Cav1 protein designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in idiopathic pulmonary fibrosis. The company also developed LTI-01, a proenzyme for treating loculated pleural effusion, alongside preclinical programs for cystic fibrosis and systemic fibrosis, although active development on these secondary programs is paused. Because its drug candidates remain in clinical and preclinical development, the company has no commercialized products, generates no product sales revenue, and currently lacks commercial customers or internal sales, marketing, and distribution infrastructure.
The company operates without internal manufacturing facilities, relying entirely on third-party contract manufacturers for drug supplies. Its clinical development activities span multiple countries, including clinical trial sites located across the United States, the United Kingdom, Germany, Poland, Belgium, Australia, and New Zealand. The provided text does not state the company's headquarters location.
Summary of the business section of Rein Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rein Therapeutics, Inc.
- Headquarters
- Austin, TX
- Address
- 12407 N. Mopac Expy., Suite 250 #390 78758
- Phone
- (737) 802-1989
- Website
- reintx.com
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., New York, NY
Stock & identifiers
- Ticker
- RNTX
- Former tickers
- ALRN until Jan 10, 2025
- Exchange
- Nasdaq
- IPO date
- Jun 29, 2017
- Shares outstanding
- 86M, Aug 12, 2026
- Public float
- $32.26M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Nov 11, 2022
- SEC CIK
- 1420565
- CUSIP
- 00887A204
- ISIN
- US00887A2042
- FIGI
- BBG002454KR1
- Share class FIGI
- BBG002454KS0
- EIN
- 13-4196017
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James Brian Windsor | See Remarks, Director | 27,432 |
| Rickenbach Josef H. Von | Director | 62,514 |
| Alan A. Musso | Director | – |
| Manuel Aivado | Director | 1,000 |
| Reinhard J. Ambros | Director | 2,549,982 |
| William Fairey | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brian Windsor | $882.70K | $1.31M | $0 | $-55 | – |
| FY2025 Timothy MCunningham | $433.94K | $433.94K | $0 | $-55 | – |
| FY2024 Brian Windsor | $1.76M | $1.77M | $475.96K | $-3 | – |
| FY2024 Manuel CAlves Aivado | $1.33M | $1.16M | $475.96K | $-3 | – |
| FY2024 Manuel CAlvesaivado | $1.33M | $1.16M | $475.96K | $-3 | – |
| FY2023 | $0 | $0 | $417.90K | $29 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Brian Windsor, Ph.D. President and Chief Executive Officer | $575.00K | $287.50K | $20.20K | $882.70K | -50% |
| Timothy M. Cunningham Interim Chief Financial Officer | $433.94K | – | – | $433.94K | +57% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 29, 2017
- Offer price
- $15.00
- Securities offered
- 3,750,000
- Gross proceeds
- $56.25M
- Exchange
- Nasdaq
- First trading day
- Jun 29, 2017
- First-day close
- $10.80-28.0%
- Lock-up ends (est.)
- Dec 26, 2017
“The public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 10 full-time employees, including a total of two employees with M.D.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?